SCHEMBL7078787

SCHEMBL7078787

O=C(CC(=O)c1nccs1)c1cc(Cc2ccccc2)cc(CN2CCCCS2(=O)=O)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G4A P47712 1/20 0.39
CES1 P23141 1/20 0.38
PTGER3 P43115 1/20 0.34
GRM2 Q14416 1/20 0.34
HRH1 P35367 1/20 0.34
F2 P00734 2/20 0.33
F10 P00742 2/20 0.33
CYP11B2 P19099 2/20 0.33
ADORA2A P29274 1/20 0.33
ADORA2B P29275 1/20 0.33
PARP1 P09874 1/20 0.33
CALCA P06881 1/20 0.33
GRM5 P41594 1/20 0.33
POLB P06746 2/20 0.32
CYP11B1 P15538 1/20 0.32
CACNA2D1 P54289 1/20 0.32
CDK1 P06493 1/20 0.32
CDK4 P11802 1/20 0.32
CDK2 P24941 1/20 0.32
MAOB P27338 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7081226 0.97 PLA2G4A (0.39) PLA2G4ACES1PTGER3GRM2HRH1
SCHEMBL7078791 0.92 PLA2G4A (0.39) PLA2G4ACES1PTGER3HRH1F2
SCHEMBL7085125 0.89 PLA2G4A (0.40) PLA2G4ACES1PTGER3HRH1F2
SCHEMBL7082113 0.81 GRM2 (0.35) GRM2CYP11B2CALCAGRM5CDK1
SCHEMBL7077505 0.79 ACKR3 (0.36) GRM2GRM5CDK1CDK4CDK2
SCHEMBL7082837 0.77 LMNA (0.43) GRM2CYP11B2POLBCYP11B1MEN1
SCHEMBL7077747 0.77 ACKR3 (0.36) GRM2POLBCDK1CDK4CDK2
SCHEMBL7081087 0.75 SMN1; SMN2 (0.40) PLA2G4ACES1HRH1F2F10
SCHEMBL7082794 0.70 KMT2A (0.35) GRM2GRM5MEN1KMT2A
SCHEMBL7082096 0.70 SMO (0.36) GRM2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030229079-A1 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof PAYNE LINDA S (US) 2003-12-11 US claimed
US-20030229079-A1 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof PAYNE LINDA S (US) 2003-12-11 US disclosed
EP-1196384-A4 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF MERCK & CO INC (US) 2002-10-23 EP disclosed
EP-1196384-A1 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF Merck & Co., Inc. (US) 2002-04-17 EP disclosed
WO-2001000578-A1 1-(AROMATIC- OR HETEROAROMATIC-SUBSTITUTED)-3-(HETEROAROMATIC SUBSTITUTED)-1,3-PROPANEDIONES AND USES THEREOF MERCK & CO., INC. (US) 2001-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229079-A1 1-(Aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof CYP2S1, IMPDH1, IDO1 PLA2G4A 3729/4885CES1 543/4885PTGER3 1354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.